SLC5A2 and Stroke: Despite the fact that stroke reduction has not been directly demonstrated with the use of SGLT-2 inhibitors, diabetic patients with atherosclerotic disease receive enormous benefit in the global reduction of cardiovascular events, notably reduction of morbidity from heart failure.